3
Cytologic Screening Programs
59. Wang KK, Wongkeesong M, Buttar NS.
American Gastroenterological Association
medical position statement: role of the
gastroenterologist in the management of
esophageal carcinoma.
Gastroenterology
2005;128:1468-1470.
60. Dong Z, Tang P, Li L, Wang G. The
strategy for esophageal cancer control in
high-risk areas of China.
Jpn J Clin Oncol
2002;32(suppl 1):S10-S12.
61. Dawsey S, Shen Q, Nieberg RK, et al.
Studies of esophageal balloon cytology
in Linxian, China.
CA Epidem Biomar Prev
1997;6:121-130.
62. National Cancer Institute. U.S. National
Institutes of Health. Screening for bladder
and other urothelial cancers. Acessed on
2007 Mar 31. Available at: http://www.
cancer.gov/cancertopics/pdq/screening/
bladder/HealthProfessional/page2
63. Burch JD, Rohan TE, Howe GR, et al. Risk
of bladder cancer by source and type of
tobacco exposure: a case-control study.
Intern J Cancer
1989;44(4):622-628.
64. Cole P, Hoover R, Friedell GH. Occupa-
tion and cancer of the lower urinary tract.
Cancer
1972;29(5):1250-1260.
65. Brownson RC, Chang JC, Davis JR.
Occupation, smoking, and alcohol in
epidemiology of bladder cancer.
Am J Pub
Health
1987;77:1296-1300.
66. Anton-Culver H, Lee-Feldstein A, Taylor
TH. Occupation and bladder cancer risk.
Am J Epidem
1992;136:89-94.
67. Richard K, Dziura B, Hornish A. Cell
block preparation as a diagnostic tech-
nique complementary to fluid-based
monolayer cervicovaginal specimens.
Acta Cytol
1999;43(1):69-73.
68. Diaz-Rosario LA, Kabawat SE. Cell
block preparation by inverted filter
sedimentation is useful in the differential
diagnosis of atypical glandular cells of
undetermined significance in ThinPrep
specimens.
Cancer
2000;90(5):
265-272.
69. Massarani-Wafai R, Bakhos R, Wojcik
EM, et al. Evaluation of cellular residue
in the ThinPrep PreservCyt vial.
Diagn
Cytopathol
2000;23(3):208-212.
70. Longatto Filho A, Pereira SM, Di Loreto
C, et al. DCS liquid-based system is
more effective than conventional smears
to diagnosis of cervical lesions: study
in high-risk population with biopsy-
based confirmation.
Gynecol Oncol
2005;97(2):497-500.
71. Dahl MB, Ejersbo D, Holund B.
Cause and follow-up of inadequate
cervical smears in the county of Funen.
Ugeskr Laeger
2002;164(37):
4280-4283.
72. Alves VA, Bibbo M, Schmitt FC, et
al. Comparison of manual and auto-
mated methods of liquid-based cytol-
ogy. A morphologic study.
Acta Cytol
2004;48(2):187-193.
73. Nieminen P. Task force nine: Automated
prescreening and rescreening.
Inter-
national Conference on the Fight against
Cervical Cancer, Chicago
, 2000.
74. Engeland A, Haldorsen T, Tretli S, et al.
Prediction of cancer incidence in the
Nordic countries up to the years 2000
and 2010. A collaborative study of the
five Nordic Cancer Registries.
APMIS
1993;38(Suppl):1-124.
75. Hristova L, Hakama M, Effect of screen-
ing for cancer in the Nordic countries on
deaths, cost and quality of life up to the
year 2017.
Acta Oncol
1997;36(Suppl 9):
1-60.
76. Parkin DM, Whelan SL, Ferlay J, et al.
(eds),
Cancer Incidence in Five Continents,
vol. VII, IARC Scientific Publications. No.
143. Lyon: IARC, 1997,
77. Moller B, Fekjaer H, Hakulinen T, et al.
Prediction of cancer incidence in Nordic
countries up to the year 2020.
Eur J
Cancer Prev
2002;11(Suppl 1):S1-S96.
57
previous page 62 ComprehensiveCytopathology 1104p 2008 read online next page 64 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off